Subscribe To

Price Alert Latest News Economic Calendar News

ETNB / This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG). SVB Leerink views these results as 'strong' and says they provide a clear win for the company as. Read More

Demo Live Account See Partner Details

Content Topics

This

Analyst

Thinks

89bio

Pegozafermin

Data

Exceeded

89bio s

Expectations

Stock

ETNB

Posted: Jul 11 2022, 14:24

Author Name: Benzinga

ETNB News

By Seeking Alpha
October 26, 2023

89bio's Low Price Presents An Opportunity

89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive

By GlobeNewsWire
October 17, 2023

89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference

SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and

By The Motley Fool
October 10, 2023

Why Shares of 89bio Plummeted on Tuesday

89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases.

By Proactive Investors
August 28, 2023

89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic

Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from th

By Seeking Alpha
August 10, 2023

89bio, Inc.: A Big Bet On NASH

89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-li

By Market Watch
June 13, 2023

89bio shares rise as analysts see improved outlook for NASH treatments

Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the

By Zacks Investment Research
May 29, 2023

89BIO (ETNB) Just Overtook the 20-Day Moving Average

89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed a

By Seeking Alpha
May 28, 2023

89bio: Great Prospects After Excellent Phase 2 Data

ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.